Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14365/5017
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Akyıldız, Zehra İlke | - |
dc.contributor.author | Baysan, O. | - |
dc.date.accessioned | 2023-12-26T07:28:48Z | - |
dc.date.available | 2023-12-26T07:28:48Z | - |
dc.date.issued | 2023 | - |
dc.identifier.issn | 1694-7886 | - |
dc.identifier.uri | https://doi.org/10.24969/hvt.2023.443 | - |
dc.identifier.uri | https://hdl.handle.net/20.500.14365/5017 | - |
dc.description.abstract | [No abstract available] | en_US |
dc.language.iso | en | en_US |
dc.publisher | Bishkek: Center for Scientific Research and Development of Education | en_US |
dc.relation.ispartof | Heart, Vessels and Transplantation | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | acetazolamide | en_US |
dc.subject | amino terminal pro brain natriuretic peptide | en_US |
dc.subject | angiotensin receptor antagonist | en_US |
dc.subject | beta adrenergic receptor blocking agent | en_US |
dc.subject | canagliflozin | en_US |
dc.subject | dapagliflozin | en_US |
dc.subject | dipeptidyl carboxypeptidase inhibitor | en_US |
dc.subject | diuretic agent | en_US |
dc.subject | empagliflozin | en_US |
dc.subject | finerenone | en_US |
dc.subject | furosemide | en_US |
dc.subject | hydrochlorothiazide | en_US |
dc.subject | insulin | en_US |
dc.subject | iron | en_US |
dc.subject | iron isomaltose | en_US |
dc.subject | loop diuretic agent | en_US |
dc.subject | mineralocorticoid antagonist | en_US |
dc.subject | sodium glucose cotransporter 2 inhibitor | en_US |
dc.subject | sotagliflozin | en_US |
dc.subject | torasemide | en_US |
dc.subject | acute heart failure | en_US |
dc.subject | add on therapy | en_US |
dc.subject | adverse outcome | en_US |
dc.subject | blood pressure | en_US |
dc.subject | cardiologist | en_US |
dc.subject | cardiology | en_US |
dc.subject | cardiovascular mortality | en_US |
dc.subject | cardiovascular risk | en_US |
dc.subject | cerebrovascular accident | en_US |
dc.subject | chronic disease | en_US |
dc.subject | chronic kidney failure | en_US |
dc.subject | comorbidity | en_US |
dc.subject | coronavirus disease 2019 | en_US |
dc.subject | death | en_US |
dc.subject | diabetes mellitus | en_US |
dc.subject | diabetic ketoacidosis | en_US |
dc.subject | diabetic nephropathy | en_US |
dc.subject | disease course | en_US |
dc.subject | drug efficacy | en_US |
dc.subject | drug safety | en_US |
dc.subject | drug tolerability | en_US |
dc.subject | Editorial | en_US |
dc.subject | estimated glomerular filtration rate | en_US |
dc.subject | European | en_US |
dc.subject | evaluation study | en_US |
dc.subject | evidence based practice | en_US |
dc.subject | follow up | en_US |
dc.subject | health care access | en_US |
dc.subject | heart failure | en_US |
dc.subject | heart failure with preserved ejection fraction | en_US |
dc.subject | heart failure with reduced ejection fraction | en_US |
dc.subject | heart infarction | en_US |
dc.subject | heart left ventricle ejection fraction | en_US |
dc.subject | heart muscle revascularization | en_US |
dc.subject | hemodialysis | en_US |
dc.subject | hemodialysis patient | en_US |
dc.subject | hospital patient | en_US |
dc.subject | hospitalization | en_US |
dc.subject | human | en_US |
dc.subject | iron deficiency | en_US |
dc.subject | iron therapy | en_US |
dc.subject | medical society | en_US |
dc.subject | meta analysis (topic) | en_US |
dc.subject | morbidity | en_US |
dc.subject | non insulin dependent diabetes mellitus | en_US |
dc.subject | outcomes research | en_US |
dc.subject | practice guideline | en_US |
dc.subject | prognosis | en_US |
dc.subject | randomized controlled trial (topic) | en_US |
dc.subject | risk reduction | en_US |
dc.subject | sensitivity analysis | en_US |
dc.subject | treatment outcome | en_US |
dc.subject | tricuspid valve repair | en_US |
dc.title | Key messages to comprehend: 2023 Focused Update of the 2021 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure | en_US |
dc.type | Editorial | en_US |
dc.identifier.doi | 10.24969/hvt.2023.443 | - |
dc.identifier.scopus | 2-s2.0-85179782826 | en_US |
dc.department | İzmir Ekonomi Üniversitesi | en_US |
dc.authorscopusid | 25951323500 | - |
dc.authorscopusid | 10243313600 | - |
dc.identifier.volume | 7 | en_US |
dc.identifier.issue | 4 | en_US |
dc.institutionauthor | … | - |
dc.relation.publicationcategory | Diğer | en_US |
dc.identifier.scopusquality | Q4 | - |
dc.identifier.wosquality | N/A | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | reserved | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
item.openairetype | Editorial | - |
crisitem.author.dept | 09. Faculty of Medicine | - |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
5017.pdf Restricted Access | 200.44 kB | Adobe PDF | View/Open Request a copy |
CORE Recommender
Page view(s)
80
checked on Nov 25, 2024
Download(s)
2
checked on Nov 25, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.